{"id":"bcma","name":"BCMA","symbol":"TNFRSF17","route":"/targets/bcma/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11913","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048462","uniprot":"https://www.uniprot.org/uniprotkb/Q02223/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q02223","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4523587","open-targets":"https://platform.opentargets.org/target/ENSG00000048462","civic":"https://civicdb.org/genes/608/summary","oncokb":"https://www.oncokb.org/gene/TNFRSF17","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TNFRSF17","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=TNFRSF17","depmap":"https://depmap.org/portal/gene/TNFRSF17?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000048462-TNFRSF17","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/608","omim":"https://www.omim.org/entry/109545"}],"products":[{"id":"anitocabtagene-autoleucel","name":"Anitocabtagene autoleucel","status":"phase-3","modality":"CAR-T (BCMA, D-domain binder)","route":"/drugs/anitocabtagene-autoleucel/"},{"id":"azd0120","name":"AZD0120","status":"phase-3","modality":"CAR-T cell therapy","route":"/drugs/azd0120/"},{"id":"azd4045","name":"AZD4045","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/azd4045/"},{"id":"belantamab-mafodotin","name":"Belantamab mafodotin","status":"approved","modality":"ADC","route":"/drugs/belantamab-mafodotin/"},{"id":"ciltacabtagene-autoleucel","name":"Ciltacabtagene autoleucel","status":"approved","modality":"CAR-T (BCMA)","route":"/drugs/ciltacabtagene-autoleucel/"},{"id":"elranatamab","name":"Elranatamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/elranatamab/"},{"id":"equecabtagene-autoleucel","name":"Equecabtagene autoleucel","status":"approved","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","route":"/drugs/equecabtagene-autoleucel/"},{"id":"gc012f","name":"GC012F","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/gc012f/"},{"id":"idecabtagene-vicleucel","name":"Idecabtagene vicleucel","status":"approved","modality":"CAR-T (BCMA)","route":"/drugs/idecabtagene-vicleucel/"},{"id":"isb-2001","name":"ISB 2001","status":"phase-1","modality":"Trispecific T-cell engager (BCMA x CD38 x CD3)","route":"/drugs/isb-2001/"},{"id":"linvoseltamab","name":"Linvoseltamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/linvoseltamab/"},{"id":"nxc-201-car-t","name":"NXC-201 CAR-T","status":"phase-2","modality":"CAR-T cell therapy","route":"/drugs/nxc-201-car-t/"},{"id":"teclistamab","name":"Teclistamab","status":"approved","modality":"Bispecific T-cell engager (BCMA×CD3)","route":"/drugs/teclistamab/"},{"id":"zevorcabtagene-autoleucel","name":"Zevorcabtagene autoleucel","status":"approved","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","route":"/drugs/zevorcabtagene-autoleucel/"}],"trials":[{"id":"nct06956170","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","nct":"NCT06956170","phase":"3","status":"active"},{"id":"nct06868654","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","nct":"NCT06868654","phase":"3","status":"active"},{"id":"nct06868667","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","nct":"NCT06868667","phase":"3","status":"active"},{"id":"majestec-3","name":"MajesTEC-3","nct":"NCT05083169","phase":"3","status":"positive"},{"id":"dreamm-7","name":"DREAMM-7","nct":"NCT04246047","phase":"3","status":"positive"},{"id":"dreamm-8","name":"DREAMM-8","nct":"NCT04484623","phase":"3","status":"positive"},{"id":"cartitude-4","name":"CARTITUDE-4","nct":"NCT04181827","phase":"3","status":"positive"},{"id":"karmma-3","name":"KarMMa-3","nct":"NCT03651128","phase":"3","status":"positive"},{"id":"nct04162210","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","nct":"NCT04162210","phase":"3","status":"active"},{"id":"nct06464991","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","nct":"NCT06464991","phase":"3","status":"recruiting"},{"id":"nct06413498","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","nct":"NCT06413498","phase":"3","status":"active"},{"id":"nct06208150","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","nct":"NCT06208150","phase":"3","status":"active"},{"id":"nct05572515","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","nct":"NCT05572515","phase":"3","status":"active"},{"id":"nct06679101","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","nct":"NCT06679101","phase":"3","status":"recruiting"},{"id":"nct05552222","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","nct":"NCT05552222","phase":"3","status":"recruiting"},{"id":"nct07393282","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","nct":"NCT07393282","phase":"3","status":"recruiting"},{"id":"nct06045806","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","nct":"NCT06045806","phase":"3","status":"active"},{"id":"nct05623020","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","nct":"NCT05623020","phase":"3","status":"recruiting"},{"id":"nct05020236","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","nct":"NCT05020236","phase":"3","status":"recruiting"},{"id":"nct05730036","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","nct":"NCT05730036","phase":"3","status":"recruiting"},{"id":"cartitude-5","name":"CARTITUDE-5","nct":"NCT04923893","phase":"3","status":"active"},{"id":"cartitude-6","name":"CARTITUDE-6","nct":"NCT05257083","phase":"3","status":"active"},{"id":"nct06152575","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","nct":"NCT06152575","phase":"3","status":"recruiting"},{"id":"nct05317416","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","nct":"NCT05317416","phase":"3","status":"active"},{"id":"immagine-1","name":"iMMagine-1","nct":"NCT05396885","phase":"2","status":"positive"},{"id":"magnetismm-3","name":"MagnetisMM-3","nct":"NCT04649359","phase":"2","status":"positive"},{"id":"nct06140524","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","nct":"NCT06140524","phase":"2","status":"recruiting"},{"id":"nct05955508","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","nct":"NCT05955508","phase":"2","status":"active"},{"id":"nct06550895","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","nct":"NCT06550895","phase":"2","status":"active"},{"id":"nct06577025","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","nct":"NCT06577025","phase":"2","status":"active"},{"id":"nct04133636","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","nct":"NCT04133636","phase":"2","status":"active"},{"id":"nct07149857","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","nct":"NCT07149857","phase":"2","status":"recruiting"},{"id":"nct07227311","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","nct":"NCT07227311","phase":"2","status":"recruiting"},{"id":"nct05594797","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","nct":"NCT05594797","phase":"2","status":"recruiting"},{"id":"nct07150104","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","nct":"NCT07150104","phase":"1/2","status":"active"},{"id":"nct07217119","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","nct":"NCT07217119","phase":"1/2","status":"active"},{"id":"nct07217184","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","nct":"NCT07217184","phase":"1/2","status":"active"},{"id":"nct07084896","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","nct":"NCT07084896","phase":"1/2","status":"active"},{"id":"nct07150091","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","nct":"NCT07150091","phase":"1/2","status":"active"},{"id":"fumanba-1","name":"FUMANBA-1","nct":"NCT05066646","phase":"1/2","status":"positive"},{"id":"linker-mm1","name":"LINKER-MM1","nct":"NCT03761108","phase":"1/2","status":"positive"},{"id":"lummicar-1","name":"LUMMICAR STUDY 1","nct":"NCT03975907","phase":"1/2","status":"positive"},{"id":"majestec-1","name":"MajesTEC-1","nct":"NCT04557098","phase":"1/2","status":"positive"},{"id":"cartitude-1","name":"CARTITUDE-1","nct":"NCT03548207","phase":"1/2","status":"positive"},{"id":"legend-2","name":"LEGEND-2","nct":"NCT03090659","phase":"1/2","status":"positive"},{"id":"nct07681596","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT07681596","phase":"1/2","status":"recruiting"},{"id":"nct06235229","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","nct":"NCT06235229","phase":"1/2","status":"recruiting"},{"id":"nct04586426","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","nct":"NCT04586426","phase":"1/2","status":"active"},{"id":"nct06669247","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","nct":"NCT06669247","phase":"1/2","status":"recruiting"},{"id":"nct06988488","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","nct":"NCT06988488","phase":"1/2","status":"recruiting"},{"id":"nct05714839","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","nct":"NCT05714839","phase":"1/2","status":"recruiting"},{"id":"nct07455851","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","nct":"NCT07455851","phase":"1/2","status":"recruiting"},{"id":"nct05828511","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","nct":"NCT05828511","phase":"1/2","status":"recruiting"},{"id":"nct05850234","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","nct":"NCT05850234","phase":"1/2","status":"recruiting"},{"id":"nct06106945","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","nct":"NCT06106945","phase":"1/2","status":"recruiting"},{"id":"nct03915184","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","nct":"NCT03915184","phase":"1/2","status":"active"},{"id":"nct04126200","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","nct":"NCT04126200","phase":"1/2","status":"active"},{"id":"nxc-201-mm","name":"HBI0101 (NXC-201) multiple myeloma phase 1","nct":"NCT04720313","phase":"1","status":"active"},{"id":"nct05862012","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","nct":"NCT05862012","phase":"1","status":"recruiting"}],"pathways":[],"companies":["abbvie","arcellx","astrazeneca","aurigene","bms","carsgen","cartesian-therapeutics","cullinan-therapeutics","gilead","glenmark","gracell-biotechnologies","gsk","heidelberg-pharma","iaso-bio","immix-biopharma","innovent","johnson-johnson","kelonia-therapeutics","legend-biotech","orna-therapeutics","pfizer","poseida-therapeutics","regeneron"],"keyPapers":["paper-cartitude-4-cilta-cel-nejm-2023","paper-nxc-201-hbi0101-asherie-haematologica-2023","paper-karmma-3-ide-cel-nejm-2023","paper-magnetismm-3-elranatamab-natmed-2023","paper-majestec-1-teclistamab-nejm-2022","paper-cartitude-1-cilta-cel-lancet-2021"],"hotspots":[],"openQuestions":[{"id":"bcma-sequencing","question":"In what order should BCMA CAR-T, BCMA bispecifics and GPRC5D-directed therapy be given, and does antigen loss after one preclude the next?","stage":"clinical","actor":"clinic","source":{"label":"CARTITUDE-4, NEJM 2023","url":"https://doi.org/10.1056/NEJMoa2303379"}}],"assays":[],"resistance":[{"class":"bcma-directed","mechanism":"BCMA antigen loss (biallelic TNFRSF17 deletion, extracellular mutations)","category":"antigen"},{"class":"bcma-directed","mechanism":"T-cell exhaustion and low fitness","category":"immune-evasion"},{"class":"bcma-directed","mechanism":"Soluble BCMA decoy","category":"pharmacology"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}